See more : Bird Construction Inc. (BIRDF) Income Statement Analysis – Financial Results
Complete financial analysis of CaliPharms, Inc. (KGET) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of CaliPharms, Inc., a leading company in the Agricultural Inputs industry within the Basic Materials sector.
- Ohishi Sangyo Co., Ltd. (3943.T) Income Statement Analysis – Financial Results
- Standard Uranium Ltd. (STND.V) Income Statement Analysis – Financial Results
- Capitala Finance Corp. (CPTA) Income Statement Analysis – Financial Results
- Pharos Energy plc (PHAR.L) Income Statement Analysis – Financial Results
- Disc Medicine, Inc. (IRON) Income Statement Analysis – Financial Results
CaliPharms, Inc. (KGET)
About CaliPharms, Inc.
CaliPharms, Inc. engages in the medicinal Cannabis Industry in the United States. It focuses on the THC and CBD beverage industry. The company was formerly known as Kleangas Energy Technologies, Inc. and changed its name to CaliPharms, Inc. in January, 2017. CaliPharms, Inc. is based in Temecula, California.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2013 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 12.00K | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 12.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.36M | 357.86K | 340.28K | 184.18K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.36M | 357.86K | 340.28K | 184.18K |
| Cost & Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.36M | 357.86K | 340.28K | 184.18K |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 76.65K | 83.73K | 618.35K | 144.55K |
| Depreciation & Amortization | 228.49K | 236.56K | 206.30K | 171.86K | 161.14K | 52.52K | 22.82K | 0.00 | 0.00 |
| EBITDA | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -1.35M | -357.86K | -340.28K | -184.18K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -11,222.67% | 0.00% | 0.00% | 0.00% |
| Operating Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -1.35M | -357.86K | -340.28K | -184.18K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -11,222.67% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -76.65K | -83.73K | -618.35K | 183.97K |
| Income Before Tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -1.42M | -441.59K | -958.63K | -213.25K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -11,861.40% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -1.42M | -441.59K | -958.63K | -213.25K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -11,861.40% | 0.00% | 0.00% | 0.00% |
| EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Weighted Avg Shares Out | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 10.78B | 6.46B | 6.35B | 2.26B |
| Weighted Avg Shares Out (Dil) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 10.78B | 6.46B | 6.35B | 2.26B |
Source: https://incomestatements.info
Category: Stock Reports